Archynetys Live news trend intelligence
◼ Archived Business 🔮 Archynetys predicts: still trending tomorrow — graded ✗ wrong

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI is acquiring cancer-monitoring firm Personalis for $1.5 billion, though market reaction has seen shares for both companies dive.

By · Published July 23, 2026  16:11 UTC · Updated July 23, 2026  17:51 UTC

10sources
10articles
8velocity
+0%since first seen
91d agofirst detected
Text:
🤖 AI Dossier

Evidence dossier

Intelligence passport

81/100 Exceptional
10distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

📍 How it ended

Tempus AI acquired cancer-monitoring firm Personalis in a $1.5 billion stock deal to expand its precision oncology platform. Following the announcement, shares for both companies sank.

Epilogue added 88d ago, after coverage quieted.

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The story so far

⚡ Executive Intelligence Takeaways Corroborated across 10 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 10 distinct news outlets with 10 published articles, achieving a live velocity of 8.
  • Primary Driver: Tempus AI is acquiring cancer-monitoring firm Personalis for $1.5 billion, though market reaction has seen shares for both companies dive.
  • Predictive Outlook: Archynetys algorithmic models forecast this story will remain a dominant headline through tomorrow.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

Tempus AI has entered an agreement to acquire Personalis in a $1.5 billion stock deal. The acquisition is intended to expand Tempus AI's precision oncology platform by more tightly integrating molecular residual disease (MRD) capabilities.

Coverage from Reuters, Barron's, and Investor's Business Daily emphasizes the immediate market reaction, noting that shares for both companies sank following the announcement. Technical and legal details reported by Law360 identify Latham and Cooley as the firms steering the deal.

Future developments center on the integration of Personalis's cancer genomics and monitoring tools into the AI-enabled platform provided by Tempus AI.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 88d ago.

Coverage (10)

The obvious questions

How much is Tempus AI paying for Personalis?

The acquisition is valued at $1.5 billion.

What is the primary goal of the acquisition?

Tempus AI aims to expand its precision oncology platform and integrate molecular residual disease (MRD) monitoring.

How did the stock market respond to the news?

According to Barron's and Investor's Business Daily, shares for both Tempus AI and Personalis sank.

📊 AUDIENCE & LONGEVITY PULSE

How do you expect this trend to evolve over the next 24 hours?

Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.

Select an assessment to vote. Verified Reader Intelligence

Topics

Tempus AI Personalis Precision Oncology Cancer Genomics M&A

From around our network

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →